NFKB1 and colitis: In intestinal inflammatory diseases (UC, Crohn’s disease), nanopolysaccharides repair the intestinal barrier, regulate gut microbiota, and inhibit the NF-κB/MAPK pathways—DSS-induced colitis models confirm their ability to reduce mucosal damage and inflammatory factor levels, laying the foundation for UC treatment (267, 268).